The US FDA's work over the years to speed production of industry and stakeholder guidance may be curtailed by a White House directive requiring the Office of Management and Budget review all of them before they are released.
Agency guidance, in addition to proposed and final rules, will undergo OMB review to receive an economic impact determination, which...